Page 156 - Read Online

Page 16 of 17 Sharma et al. Microbiome Res Rep 2024;3:3 https://dx.doi.org/10.20517/mrr.2023.51

2021;22:8070. DOI PubMed PMC
43. Tojo R, Suárez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J
Gastroenterol 2014;20:15163-76. DOI PubMed PMC
44. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI
45. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a
histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. DOI
46. Sarhadi V, Mathew B, Kokkola A, et al. Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal
stromal tumors. Gut Pathog 2021;13:11. DOI PubMed PMC
47. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Science 2015;350:1084-9. DOI PubMed PMC
48. Feldman M, Friedman LS, Brandt LJ. Sleisenger and fordtran’s gastrointestinal and liver disease. Available from: https://www.
sciencedirect.com/book/9781416061892/sleisenger-and-fordtrans-gastrointestinal-and-liver-disease. [Last accessed on 31 Oct 2023].
DOI
49. Devi TB, Devadas K, George M, et al. Low Bifidobacterium abundance in the lower gut microbiota is associated with helicobacter
pylori-related gastric ulcer and gastric cancer. Front Microbiol 2021;12:631140. DOI PubMed PMC
50. Arboleya S, Watkins C, Stanton C, Ross RP. Gut bifidobacteria populations in human health and aging. Front Microbiol
2016;7:1204. DOI PubMed PMC
51. Choi Y, Kim N, Kim KW, et al. Gastric cancer in older patients: a retrospective study and literature review. Ann Geriatr Med Res
2022;26:33-41. DOI PubMed PMC
52. Cancer.Net. Stomach Cancer: Risk Factors. Available from: https://www.cancer.net/cancer-types/stomach-cancer/risk-factors. [Last
accessed on 31 Oct 2023].
53. Hu JX, Zhao CF, Chen WB, et al. Pancreatic cancer: a review of epidemiology, trend, and risk factors. World J Gastroenterol
2021;27:4298-321. DOI PubMed PMC
54. Wang XY, Sun ZX, Makale EC, et al. Gut microbial profile in patients with pancreatic cancer. Jundishapur J Microbiol
2022;15:e122386. DOI
55. Szkandera J, Stotz M, Eisner F, et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a
large cohort of pancreatic cancer patients. PLoS One 2013;8:e78225. DOI PubMed PMC
56. Kim Y, Lee D, Kim D, et al. Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by
Bifidobacterium adolescentis SPM0212. Arch Pharm Res 2008;31:468-73. DOI
57. Deo SVS, Sharma J, Kumar S. GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical
oncologists. Ann Surg Oncol 2022;29:6497-500. DOI
58. Youssef O, Lahti L, Kokkola A, et al. Stool microbiota composition differs in patients with stomach, colon, and rectal neoplasms. Dig
Dis Sci 2018;63:2950-8. DOI PubMed PMC
59. Wang Z, Su C. Effects of folic acid deficiency on genetic damage in colorectal cancer cells. Am J Transl Res 2023;15:3162-71.
PubMed PMC
60. Kim Y. Current status of folic acid supplementation on colorectal cancer prevention. Curr Pharmacol Rep 2016;2:21-33. DOI
61. Sugahara H, Odamaki T, Hashikura N, Abe F, Xiao JZ. Differences in folate production by bifidobacteria of different origins. Biosci
Microbiota Food Health 2015;34:87-93. DOI PubMed PMC
62. Waszkiewicz N, Szajda SD, Konarzewska-Duchnowska E, et al. Serum β-glucuronidase as a potential colon cancer marker: a
preliminary study. Postepy Hig Med Dosw 2015;69:436-9. DOI
63. Molan AL, Liu Z, Plimmer G. Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon
cancer in humans. Phytother Res 2014;28:416-22. DOI PubMed
64. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017;41:3-14. DOI PubMed
65. D’Amico F, Perrone AM, Rampelli S, et al. Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are
related to therapeutic outcome. Cancers 2021;13:3999. DOI PubMed PMC
66. Warburg O. On the origin of cancer cells. Science 1956;123:309-14. DOI PubMed
67. Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front
Pharmacol 2018;9:1300. DOI PubMed PMC
68. Badgeley A, Anwar H, Modi K, Murphy P, Lakshmikuttyamma A. Effect of probiotics and gut microbiota on anti-cancer drugs:
mechanistic perspectives. Biochim Biophys Acta Rev Cancer 2021;1875:188494. DOI PubMed
69. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing
chemotherapy for pediatric malignancies. Support Care Cancer 2010;18:751-9. DOI
70. Mi H, Dong Y, Zhang B, et al. Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell
immunity in colorectal cancer rats. Cell Physiol Biochem 2017;42:2330-41. DOI
71. Zaharuddin L, Mokhtar NM, Muhammad Nawawi KN, Raja Ali RA. A randomized double-blind placebo-controlled trial of
probiotics in post-surgical colorectal cancer. BMC Gastroenterol 2019;19:131. DOI PubMed PMC
72. Mizuta M, Endo I, Yamamoto S, et al. Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery,
inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial. Biosci